Home / CABA : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CABA make money? Does CABA have pricing power? What's the Earnings Whisper? Will CABA profit more as the business scales? What is CABA's management track record? Is CABA's current price justified?

Cabaletta Bio, Inc.

$2.91 +$0.70 (+31.67%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$2.73

Day Range

$2.71$3.04

Year Range

$1.82$4.23

Market Cap

474.49M

AVG Volume

4.71M

Trailing/Forward PE

-1.84/-

PEG ratio

0.15

Dividend Yield

Next Earnings Date

2026-11-09

Primary Exchange

NASDAQ

Net Income (USD)

CABA Net Income (USD) by year
Period	Net Income (USD)
2025	-167.86M
2024	-115.86M
2023	-67.67M
2022	-52.98M
2021	-46.29M
2020	-33.34M
2019	-16.94M
2018	-12.2M

Operating Income (USD)

CABA Operating Income (USD) by year
Period	Operating Income (USD)
2025	-172.24M
2024	-125.14M
2023	-74.66M
2022	-54.14M
2021	-46.31M
2020	-33.83M
2019	-18.68M
2018	-6.19M

EBITDA (USD)

CABA EBITDA (USD) by year
Period	EBITDA (USD)
2025	-164.21M
2024	-105.33M
2023	-66.25M
2022	-51.8M
2021	-45.57M
2020	-33.48M
2019	-18.58M
2018	-5.14M

Cash Flows (USD)

CABA Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-132.31M
2024	-90.43M
2023	-54.24M
2022	-48.83M
2021	-35.27M
2020	-27.41M
2019	-16.74M
2018	-2.98M

EPS (USD)

CABA EPS (USD) by year
Period	EPS (USD)
2025	-2.31
2024	-2.34
2023	-1.63
2022	-1.78
2021	-1.8
2020	-1.44
2019	-1.27
2018	-1.6

Expenses (USD)

CABA Expenses (USD) by year
Period	Expenses (USD)
2025	173.47M
2024	127.35M
2023	75.35M
2022	56.59M
2021	47.48M
2020	34.47M
2019	19.38M
2018	6.19M

Cash & Debt (USD)

CABA Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	133.6M
2024	163.96M
2023	241.25M
2022	106.55M
2021	122.22M
2020	108.66M
2019	136.2M
2018	33.02M

Debt ratios

CABA Debt ratios by year
Period	Debt ratios
2025	0.27
2024	0.55
2023	1.2
2022	0.68
2021	1.19

Return on Capital

CABA Return on Capital by year
Period	Return on Capital
2025	-149.8%
2024	-76.06%
2023	-28.65%
2022	-50.68%
2021	-39.24%
2020	-30.43%
2019	-12.25%
2018	114.13%

Shares Outstanding

CABA Shares Outstanding by year
Period	Shares Outstanding
2025	102.26M
2024	50.13M
2023	44.44M
2022	29.45M
2021	28.34M
2020	23.27M
2019	24.03M
2018	3.63M

Book Value Per Share (USD)

CABA Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	1.1
2024	3.04
2023	5.32
2022	3.55
2021	4.16
2020	4.71
2019	5.76
2018	-2.94

Total Assets (USD)

CABA Total Assets (USD) by year
Period	Total Assets (USD)
2025	165.08M
2024	185.05M
2023	253.65M
2022	116.97M
2021	126.34M
2020	114.72M
2019	141.47M
2018	34.17M

Employee Count

CABA Employee Count by year
Period	Employee Count
2025	154
2024	161
2023	101
2022	58
2021	53
2020	33
2019	22

Free Cash Flow Yield

CABA Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-35.06%
Sep 26	-37.37%
Sep 26	-29.4%
Aug 26	-32.7%
Aug 26	-32.59%
Aug 26	-37.1%
Aug 26	-45.84%
Jul 26	-47.72%
Jul 26	-47.55%
Jul 26	-45.2%
Jul 26	-42.92%
Jul 26	-40.09%
Jun 26	-42.07%
Jun 26	-45.04%
Jun 26	-42.49%
Jun 26	-39.35%
May 26	-33.84%
May 26	-35.04%
May 26	-38.64%
May 26	-33.35%
May 26	-44.01%
Apr 26	-43.86%
Apr 26	-37.61%
Apr 26	-41.34%
Apr 26	-43.71%
Mar 26	-48.28%
Mar 26	-40%
Mar 26	-38.43%
Mar 26	-37.1%
Feb 26	-35.42%
Feb 26	-40.41%
Feb 26	-42%
Feb 26	-46.85%
Jan 26	-45.76%
Jan 26	-36.98%
Jan 26	-53.45%
Jan 26	-56%
Jan 26	-53.21%
Dec 25	-53.7%
Dec 25	-49.2%
Dec 25	-49.83%
Dec 25	-46.12%
Nov 25	-45.76%
Nov 25	-56.54%
Nov 25	-50.91%
Nov 25	-67.34%
Oct 25	-47.56%
Oct 25	-69.52%
Oct 25	-60.25%
Oct 25	-74.01%
Oct 25	-70.37%
Sep 25	-72.76%
Sep 25	-78.41%
Sep 25	-93.32%
Sep 25	-101.01%
Aug 25	-118.42%
Aug 25	-105.99%
Aug 25	-100.41%
Aug 25	-126.26%
Aug 25	-136.47%
Jul 25	-118.39%
Jul 25	-117.68%
Jul 25	-112.94%
Jul 25	-120.56%
Jun 25	-125.17%
Jun 25	-109.79%
Jun 25	-98.75%
Jun 25	-79.24%
May 25	-105.09%
May 25	-112.3%
May 25	-96.81%
May 25	-151.59%
May 25	-134.62%
Apr 25	-142.04%
Apr 25	-163.99%
Apr 25	-146.66%
Apr 25	-162.51%
Mar 25	-110.17%
Mar 25	-98.14%
Mar 25	-93.83%
Mar 25	-92.3%
Feb 25	-94.34%
Feb 25	-82.89%
Feb 25	-63.01%
Feb 25	-64.44%
Jan 25	-71.45%
Jan 25	-68.31%
Jan 25	-62.32%
Jan 25	-82.1%
Jan 25	-71.15%
Dec 24	-74.57%
Dec 24	-71.75%
Dec 24	-60.55%
Dec 24	-51.75%
Nov 24	-44.7%
Nov 24	-91.32%
Nov 24	-56.36%
Nov 24	-34.43%
Nov 24	-41.67%
Oct 24	-39.54%

Price to Book

CABA Price to Book by year
Period	Price to Book
Sep 26	2.09
Sep 26	1.96
Sep 26	2.49
Aug 26	2.24
Aug 26	2.25
Aug 26	1.97
Aug 26	3.03
Jul 26	2.91
Jul 26	2.92
Jul 26	3.07
Jul 26	3.23
Jul 26	3.46
Jun 26	3.3
Jun 26	3.08
Jun 26	3.26
Jun 26	3.52
May 26	4.1
May 26	3.96
May 26	3.59
May 26	3.54
May 26	2.68
Apr 26	2.69
Apr 26	3.14
Apr 26	2.86
Apr 26	2.7
Mar 26	2.45
Mar 26	2.16
Mar 26	2.24
Mar 26	2.32
Feb 26	2.43
Feb 26	2.13
Feb 26	2.05
Feb 26	1.84
Jan 26	1.88
Jan 26	2.33
Jan 26	1.61
Jan 26	1.54
Jan 26	1.62
Dec 25	1.61
Dec 25	1.75
Dec 25	1.73
Dec 25	1.87
Nov 25	1.88
Nov 25	1.53
Nov 25	1.69
Nov 25	0.88
Oct 25	1.25
Oct 25	0.86
Oct 25	0.99
Oct 25	0.8
Oct 25	0.85
Sep 25	0.82
Sep 25	0.76
Sep 25	0.64
Sep 25	0.59
Aug 25	0.5
Aug 25	0.56
Aug 25	0.59
Aug 25	0.47
Aug 25	0.59
Jul 25	0.68
Jul 25	0.68
Jul 25	0.71
Jul 25	0.66
Jun 25	0.64
Jun 25	0.73
Jun 25	0.81
Jun 25	1.01
May 25	0.76
May 25	0.71
May 25	0.83
May 25	0.39
May 25	0.44
Apr 25	0.42
Apr 25	0.36
Apr 25	0.4
Apr 25	0.37
Mar 25	0.44
Mar 25	0.49
Mar 25	0.51
Mar 25	0.52
Feb 25	0.51
Feb 25	0.58
Feb 25	0.76
Feb 25	0.74
Jan 25	0.67
Jan 25	0.7
Jan 25	0.77
Jan 25	0.58
Jan 25	0.67
Dec 24	0.64
Dec 24	0.67
Dec 24	0.79
Dec 24	0.93
Nov 24	1.07
Nov 24	0.53
Nov 24	0.85
Nov 24	1.1
Nov 24	0.91
Oct 24	0.96

No video analysis for this stock yet. Request one from our team.

News: CABA

seekingalpha.com · 14 Sep 2026

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

globenewswire.com · 1 Sep 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.

globenewswire.com · 13 Aug 2026

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

seekingalpha.com · 26 Jun 2026

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.